# ALPHA-SYNUCLEIN E46K Research Report **Protein:** ALPHA-SYNUCLEIN E46K **Variant:** E46K **UniProt ID:** P37840 **Disease Association:** Parkinson's disease **Report Generated:** 2026-07-29 21:40 UTC **AlphaFold Confidence (pLDDT):** 59.5% **Structure Folded:** 2026-07-23 --- ## Structure Summary Alpha-synuclein is a protein whose clumping in brain cells causes Parkinson's disease, and the E46K mutation is a rare inherited form that makes people develop symptoms earlier and more severely. Scientists used AlphaFold2 to predict the three-dimensional structure of this mutant protein, obtaining a model with average confidence of 59.5 out of 100, indicating high uncertainty typical of disordered proteins. The low confidence reflects alpha-synuclein's naturally floppy structure, which paradoxically enables the harmful clumping behavior central to Parkinson's pathology. --- Alpha-synuclein is an intrinsically disordered protein (IDP) that lacks a stable three-dimensional structure under normal conditions but plays a central role in Parkinson's disease (PD) through its tendency to misfold and aggregate into toxic clumps called Lewy bodies [1]. The E46K mutation, where glutamic acid (negatively charged) is replaced by lysine (positively charged) at position 46, is one of five single-point mutations linked to familial Parkinson's disease and causes early-onset, aggressive forms of the condition [1]. This charge reversal fundamentally alters the protein's electrostatic properties, affecting how it interacts with itself and cellular membranes. The AlphaFold2 structural prediction yielded a model with an average confidence score (pLDDT) of 59.5, which falls well below the 70-point threshold typically used to indicate reliable structural predictions. This low confidence is expected rather than problematic, as alpha-synuclein is an intrinsically disordered protein that naturally exists as an ensemble of rapidly interconverting shapes rather than adopting a single stable fold [1]. The E46K mutation's effects are particularly sensitive to ionic strength conditions, with computational studies showing that different salt concentrations can modulate the relative aggregation propensity of mutant versus wild-type alpha-synuclein [1]. Because the predicted structure represents only one potential conformation of this dynamic protein, caution is warranted when interpreting specific structural features. The E46K mutation appears to enhance alpha-synuclein's aggregation propensity through altered electrostatic interactions, though the precise mechanisms remain under investigation [1]. Research demonstrates that alpha-synuclein pathology involves complex cellular processes including oxidative stress, mitochondrial dysfunction, and impaired autophagy-lysosome pathway activity [2][3]. The mutation likely promotes formation of aggregation-prone monomeric states that serve as precursors to the toxic oligomers and fibrils characteristic of Parkinson's disease [1]. Studies using preformed fibrils (PFFs) show that even small amounts of misfolded alpha-synuclein can seed aggregation of normal protein, creating a self-propagating cascade marked by phosphorylation at serine 129 [4]. Clinically, E46K carriers typically develop Parkinson's symptoms earlier than sporadic cases and may experience faster disease progression. The mutation exemplifies how single amino acid changes in intrinsically disordered proteins can dramatically alter disease risk and trajectory. Growing evidence suggests that Parkinson's pathology may originate in the gut, with enteric alpha-synuclein aggregation preceding brain involvement [5]. This gut-brain connection is particularly relevant for understanding how environmental factors interact with genetic mutations like E46K to trigger disease onset. The high structural uncertainty in this AlphaFold2 model reflects fundamental biology rather than technical limitations. For intrinsically disordered proteins like alpha-synuclein, understanding disease mechanisms requires studying dynamic conformational ensembles and aggregation pathways rather than static structures. Future research combining computational predictions with experimental techniques that capture protein dynamics will be essential for developing therapies targeting E46K and other familial Parkinson's mutations. ## Works Cited [1] Tammara et al. (2026). Combined Effects of Mutation and Ionic Strength on alpha-Synuclein Reveal Generic Features of Aggregation-Prone Monomeric States. ACS chemical neuroscience. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42411659/) [2] Tsukiboshi et al. (2026). A PARK9 iPSC-Derived Dopaminergic Neuron Model Enables Drug Screening Targeting Autophagy-Lysosome Pathway Dysfunction in Parkinson's Disease. Journal of neurochemistry. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42400323/) [3] Sayfitdinkhazhaev et al. (2026). [Parkinson's disease associated with a mutation in the glucocerebrosidase gene]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42360210/) [4] Han et al. (2026). An automated workflow for quantifying the formation of synuclein aggregates in human dopaminergic neurons. Methods (San Diego, Calif.). [PubMed](https://pubmed.ncbi.nlm.nih.gov/42297199/) [5] Giachino et al. (2026). Peripheral Immune Challenge Drives Enteric alpha-Synuclein and Tau Pathology in LRRK2 G2019S Mice. Aging and disease. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42295088/) ## Similar Research **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Activation of endogenous PRKN by structural derepression is linked to increased turnover of the E3 ubiquitin ligase.** Fiesel et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40624741/) **Synergism of IP3R and Parkin mutants identifies mitochondrial stress as an early feature of Parkinson's disease.** Dileep et al. (2026) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41235839/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) **Serum phosphorylated tau 217 in GBA1 variant carriers with and without Parkinson disease.** Menozzi et al. (2026) *Relevant to Parkinson's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41569009/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | Hereditary late-onset Parkinson disease | 0.788 | literature, genetic_association, genetic_literature | | Young adult-onset Parkinsonism | 0.773 | literature, genetic_association, genetic_literature | | Lewy body dementia | 0.742 | literature, animal_model, genetic_association, genetic_literature | | Parkinson disease | 0.711 | rna_expression, genetic_literature, clinical, literature, genetic_association | | AL amyloidosis | 0.462 | affected_pathway | | insomnia | 0.385 | literature, genetic_association | | REM sleep behavior disorder | 0.381 | literature, genetic_association | | parkinsonian-pyramidal syndrome | 0.370 | genetic_association | | Abnormality of the skeletal system | 0.336 | genetic_association | | Anxiety | 0.323 | literature, genetic_association | *...and 791 more associations* --- ## Agent Findings ### Literature (1) - **2026-07-23:** None of the provided papers directly investigated the ALPHA-SYNUCLEIN E46K variant. While several papers examined other familial SNCA mutations (A30P, A53T) and general alpha-synuclein pathology relevant to Parkinson's disease, the specific E46K variant was not mentioned in any abstract. The papers provide useful context about alpha-synuclein biology and PD mechanisms but lack direct relevance to the E46K variant specifically. ### Clinical (1) - **2026-07-23:** ### Structural (1) - **2026-07-24:** AlphaFold structure update: Baseline check: 3 structure(s) found ### Synthesis (1) - **2026-07-24:** Synthesis of 5 findings (clinical, literature, peptides, structural, supplements): The E46K variant of alpha-synuclein associated with Parkinson's disease presents a developing therap... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)